Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 31 August 1979:
Vol. 205. no. 4409, pp. 915 - 917
DOI: 10.1126/science.224454
Prev | Table of Contents | Next

Articles

Science, Vol 205, Issue 4409, 915-917
Copyright © 1979 by American Association for the Advancement of Science

articles

Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus

RB Tenser, RL Miller, and F Rapp

The incidence of trigeminal ganglion infection after corneal inoculation of guinea pigs with thymidine kinase-negative mutants of herpes simplex virus was markedly reduced compared to infection after inoculation of thymidine kinase-positive virus. Thymidine kinase-negative herpes simplex virus replicated well in ocular tissues in which dividing or potentially dividing cells were present, but not in trigeminal ganglion infection of nondividing neurons. Thymidine kinase-positive virus, however, replicated well in ocular tissues as well as in trigeminal ganglion. These results suggest that thymidine kinase expression of herpes simplex virus may be important in infections of sensory ganglia.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Role of the VP16-Binding Domain of vhs in Viral Growth, Host Shutoff Activity, and Pathogenesis.
S. S. Strand and D. A. Leib (2004)
J. Virol. 78, 13562-13572
   Abstract »    Full Text »    PDF »
Failure of Thymidine Kinase-Negative Herpes Simplex Virus To Reactivate from Latency following Efficient Establishment.
S.-H. Chen, A. Pearson, D. M. Coen, and S.-H. Chen (2004)
J. Virol. 78, 520-523
   Abstract »    Full Text »    PDF »
Replication of Herpes Simplex Virus Type 1 within Trigeminal Ganglia Is Required for High Frequency but Not High Viral Genome Copy Number Latency.
R. L. Thompson and N. M. Sawtell (2000)
J. Virol. 74, 965-974
   Abstract »    Full Text »
Experimental therapy of human glioma by means of a genetically engineered virus mutant.
R. Martuza, A Malick, J. Markert, K. Ruffner, and D. Coen (1991)
Science 252, 854-856
   Abstract »    PDF »
Progressive Esophagitis from Acyclovir-Resistant Herpes Simplex: Clinical Roles for DNA Polymerase Mutants and Viral Heterogeneity?.
S. L. Sacks, R. J. Wanklin, D. E. Reece, K. A. Hicks, K. L. Tyler, and D. M. Coen (1989)
Ann Intern Med 111, 893-899
   Abstract »    PDF »
Drugs Five Years Later: Acyclovir.
D. I. DORSKY and C. S. CRUMPACKER (1987)
Ann Intern Med 107, 859-874
   Abstract »    PDF »
Herpes Simplex Virus Infection: Biology, Treatment, and Prevention.
S. E. STRAUS, J. F. ROONEY, J. L. SEVER, M. SEIDLIN, S. NUSINOFF-LEHRMAN, and K. CREMER (1985)
Ann Intern Med 103, 404-419
   Abstract »    PDF »
Acyclovir and Suppression of Frequently Recurring Herpetic Whitlow.
O. L. LASKIN (1985)
Ann Intern Med 102, 494-495
   Abstract »    PDF »
Resistance of Herpes Simplex to Acyclovir.
H. H. BALFOUR JR. (1983)
Ann Intern Med 98, 404-406
   Abstract »    PDF »
Acyclovir for Chronic Mucocutaneous Herpes Simplex Virus Infection in Immunosuppressed Patients.
S. E. STRAUS, H. A. SMITH, C. BRICKMAN, P. de MIRANDA, C. McLAREN, and R. E. KEENEY (1982)
Ann Intern Med 96, 270-277
   Abstract »    PDF »
Acyclovir Reaches Clinical Trial.
A. M. LERNER (1982)
Ann Intern Med 96, 370-372
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)